Skip to main content
Top
Published in: General Thoracic and Cardiovascular Surgery 11/2020

01-11-2020 | NSCLC | Original Article

Short and mid-term outcomes of multimodal treatment for locally-advanced non-small cell lung cancer in elderly patients

Authors: Stefano Bongiolatti, Francesca Mazzoni, Alessandro Gonfiotti, Giulia Di Pierro, Alberto Salvicchi, Sara Borgianni, Katia Ferrari, Luca Voltolini

Published in: General Thoracic and Cardiovascular Surgery | Issue 11/2020

Login to get access

Abstract

Objective

Multimodality treatments are effective for locally advanced non-small cell lung cancer (LA-NSCLC) showing benefits in overall (OS) and disease-free survival (DFS), but these options are frequently denied to elderly patients.

Methods

The objectives of this retrospective study were: to investigate mortality, morbidity and oncological outcomes of pulmonary resection after induction therapy (IT) for NSCLC in elderly patients. We divided the cohort into two: patients < 70 years (group A) and patients ≥70 years (group B). A multivariable logistic regression was built to identify factors associated with morbidity.

Results

77 patients underwent pulmonary resection after IT, 27 were aged ≥70 years. Type of chemotherapy, surgical procedures, pathological stages were comparable between the two groups, while the preoperative use of chemo-radiation therapy regimen was more frequent in group A (p = 0.027). In-hospital mortality was similar, while the percentage of patients with complications (38% vs 48.1%, p = 0.47) and the complication rate (50% vs 77%, p = 0.01) were higher in group B, but the severity of complications was comparable. The multivariable analysis did not identify any risk factors associated with morbidity. OS at 3 years and DFS at 2 years were not different (61% vs 48.5%, p = 0.64; 61.7% vs 44%, p = 0.393).

Conclusions

Lung resection for LA-NSCLC after IT can be performed safely in selected elderly patients with favourable postoperative and mid-term oncological results.
Literature
1.
go back to reference Rivera C, Jougon J, Dahan M, Falcoz PE, Bernard A, Brouchet L. Are postoperative consequences of neoadjuvant chemotherapy for non-small cell lung cancer more severe in elderly patients? Lung Cancer. 2012;76(2):216–21.CrossRef Rivera C, Jougon J, Dahan M, Falcoz PE, Bernard A, Brouchet L. Are postoperative consequences of neoadjuvant chemotherapy for non-small cell lung cancer more severe in elderly patients? Lung Cancer. 2012;76(2):216–21.CrossRef
2.
go back to reference Yang CJ, Mayne NR, Wang H, et al. Outcomes of major lung resection after induction therapy for non-small cell lung cancer in elderly patients. Ann Thorac Surg. 2016;102(3):962–70.CrossRef Yang CJ, Mayne NR, Wang H, et al. Outcomes of major lung resection after induction therapy for non-small cell lung cancer in elderly patients. Ann Thorac Surg. 2016;102(3):962–70.CrossRef
3.
go back to reference Marquez-Medina D, Martin-Marco A, Ojanguren-Garranz A. Age does not worsen the efficacy nor tolerance to combined induction therapies in locally advanced non-small cell lung cancer. Anticancer Res. 2014;34(8):4373–6.PubMed Marquez-Medina D, Martin-Marco A, Ojanguren-Garranz A. Age does not worsen the efficacy nor tolerance to combined induction therapies in locally advanced non-small cell lung cancer. Anticancer Res. 2014;34(8):4373–6.PubMed
4.
go back to reference Pallis AG, Gridelli C, Wedding U, Faivre-Finn C, Veronesi G, Jaklitsch M, Luciani A, O'Brien M. Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol. 2014;25(7):1270–83.CrossRef Pallis AG, Gridelli C, Wedding U, Faivre-Finn C, Veronesi G, Jaklitsch M, Luciani A, O'Brien M. Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol. 2014;25(7):1270–83.CrossRef
5.
go back to reference Browner I, Purtell M. Chemotherapy in the older patient with operable non-small cell lung cancer: neoadjuvant and adjuvant regimens. Thorac Surg Clin. 2009;19(3):377–89.CrossRef Browner I, Purtell M. Chemotherapy in the older patient with operable non-small cell lung cancer: neoadjuvant and adjuvant regimens. Thorac Surg Clin. 2009;19(3):377–89.CrossRef
6.
go back to reference Detillon DDEMA, Veen EJ. Postoperative outcome after pulmonary surgery for non-small cell lung cancer in elderly patients. Ann Thorac Surg. 2018;105(1):287–93.CrossRef Detillon DDEMA, Veen EJ. Postoperative outcome after pulmonary surgery for non-small cell lung cancer in elderly patients. Ann Thorac Surg. 2018;105(1):287–93.CrossRef
7.
go back to reference Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, Leighl N, Brade A, de Perrot M, Waddell T, Liu G, Feld R, Burkes R, Cho BC, Darling G, Sun A, Keshavjee S, Bezjak A, Shepherd FA. Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol. 2011;6(3):537–44.CrossRef Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, Leighl N, Brade A, de Perrot M, Waddell T, Liu G, Feld R, Burkes R, Cho BC, Darling G, Sun A, Keshavjee S, Bezjak A, Shepherd FA. Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol. 2011;6(3):537–44.CrossRef
8.
go back to reference Martins RG, D'Amico TA, Loo BW Jr, et al. The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. J Natl Compr Canc Netw. 2012;10:599–613.CrossRef Martins RG, D'Amico TA, Loo BW Jr, et al. The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. J Natl Compr Canc Netw. 2012;10:599–613.CrossRef
9.
go back to reference Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012;93:1807–12.CrossRef Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012;93:1807–12.CrossRef
10.
go back to reference Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–80.CrossRef Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–80.CrossRef
11.
go back to reference Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30:172–8.CrossRef Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30:172–8.CrossRef
12.
go back to reference Song WA, Zhou NK, Wang W, et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol. 2010;5:510–6.CrossRef Song WA, Zhou NK, Wang W, et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol. 2010;5:510–6.CrossRef
13.
go back to reference Blumenthal GM, Bunn PA Jr, Chaft JE, et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol. 2018;13(12):1818–31.CrossRef Blumenthal GM, Bunn PA Jr, Chaft JE, et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol. 2018;13(12):1818–31.CrossRef
14.
go back to reference Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000;48(5):1475–82.CrossRef Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000;48(5):1475–82.CrossRef
15.
go back to reference Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86.CrossRef Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86.CrossRef
16.
go back to reference Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12(7):1109–21.CrossRef Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12(7):1109–21.CrossRef
18.
go back to reference Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S. Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines. Ann Oncol. 2017;28(suppl 4):1–21.CrossRef Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S. Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines. Ann Oncol. 2017;28(suppl 4):1–21.CrossRef
19.
go back to reference Hotta K, Ueoka H, Kiura K, Tabata M, Tanimoto M. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2004;46(1):61–766.CrossRef Hotta K, Ueoka H, Kiura K, Tabata M, Tanimoto M. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2004;46(1):61–766.CrossRef
20.
go back to reference Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J Clin Oncol. 2007;25(14):1898–907.CrossRef Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J Clin Oncol. 2007;25(14):1898–907.CrossRef
21.
go back to reference Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRef Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.CrossRef
22.
go back to reference Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26(1):54–9.CrossRef Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26(1):54–9.CrossRef
23.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef
24.
go back to reference Gonfiotti A, Bongiolatti S, Bertolaccini L, et al. Thoracoscopic lobectomy for locally advanced-stage non-small cell lung cancer is a feasible and safe approach: analysis from multi-institutional national database. J Vis Surg. 2017;7(3):160.CrossRef Gonfiotti A, Bongiolatti S, Bertolaccini L, et al. Thoracoscopic lobectomy for locally advanced-stage non-small cell lung cancer is a feasible and safe approach: analysis from multi-institutional national database. J Vis Surg. 2017;7(3):160.CrossRef
25.
go back to reference Hennon M, Sahai RK, Yendamuri S, Tan W, Demmy TL, Nwogu C. Safety of thoracoscopic lobectomy in locally advanced lung cancer. Ann Surg Oncol. 2011;18(13):3732–6.CrossRef Hennon M, Sahai RK, Yendamuri S, Tan W, Demmy TL, Nwogu C. Safety of thoracoscopic lobectomy in locally advanced lung cancer. Ann Surg Oncol. 2011;18(13):3732–6.CrossRef
Metadata
Title
Short and mid-term outcomes of multimodal treatment for locally-advanced non-small cell lung cancer in elderly patients
Authors
Stefano Bongiolatti
Francesca Mazzoni
Alessandro Gonfiotti
Giulia Di Pierro
Alberto Salvicchi
Sara Borgianni
Katia Ferrari
Luca Voltolini
Publication date
01-11-2020
Publisher
Springer Singapore
Keywords
NSCLC
NSCLC
Published in
General Thoracic and Cardiovascular Surgery / Issue 11/2020
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-020-01384-5

Other articles of this Issue 11/2020

General Thoracic and Cardiovascular Surgery 11/2020 Go to the issue